Tocagen Inc's shares fell nearly 80% after its experimental treatment failed to extend life of brain cancer patients in a study, the latest in a series of setbacks for patients awaiting new treatment options for the condition. The news comes a week after Bristol-Myers Squibb Co said its blockbuster cancer immunotherapy, Opdivo, failed a late-stage trial testing it in patients with glioblastoma, a type of brain cancer that killed U.S. Senator John McCain. "This has been a really difficult place to develop drugs," SVB Leerink analyst Daina Graybosch said, adding that brain cancer has one of the highest unmet need for patients, of all cancers.

By David Bautz, PhD TSX:MDNA.TO | OTC:MDNAF READ THE FULL MDNA.TO RESEARCH REPORT Business Update MDNA55 Update Medicenna Therapeutics, Inc. (TSX:MDNA.TO) (OTC:MDNAF) is developing MDNA55 for the treatment of recurrent glioblastoma (rGBM). The company is currently conducting a Phase 2b clinical trial in a total of 46 patients experiencing either first or second GBM relapse (NCT02858895). It is a

Tocagen Inc. (NASDAQ:TOCA) shareholders should be happy to see the share price up 25% in the last month. But that is...

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Tocagen Inc. (TOCA), a clinical-stage, cancer-selective gene therapy company, today announced a restructuring to focus its resources on the clinical development of Toca 511 and Toca FC. Tocagen will reduce its workforce by approximately 65%, resulting in an estimated 30 remaining full-time employees by the end of the year. The company plans to provide financial guidance in the fourth quarter of 2019.

Is Tocagen Inc. (NASDAQ:TOCA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019.

Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ...

By David Bautz, PhD TSX:MDNA.TO READ THE FULL MDNA.TO RESEARCH REPORT Financial Update On October 17, 2019, Medicenna Therapeutics Corp. (TSX:MDNA.TO) announced the closing of a previously announced public offering in which the company issued a total of 5,307,695 units, with each unit comprising one common share of stock and one-half of one common share purchase warrant, which resulted in gross

Management to host conference call today at 8:30 a.m. Eastern SAN DIEGO , Sept. 12, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced ...

SAN DIEGO , Nov. 6, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its third quarter 2019 financial results and ...

Tocagen Inc (NASDAQ: TOCA ) shares were tumbling to an all-time low Thursday following an adverse clinical trial readout.  Tocagen , a thinly traded nano-cap biotech, said Thursday morning a Phase 3 TOCA ...

Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. Upon stockholder approval, the combined company is expected to operate under the name Forte Biosciences and trade on the Nasdaq Capital Market under the ticker symbol FBRX.

By David Bautz, PhD TSX:MDNA.TO READ THE FULL MDNA.TO RESEARCH REPORT Business Update Updated Data from Phase 2b Trial Presented at Targeting Innate Immunity Congress On September 25, 2019, Medicenna Therapeutics Corp. (TSX:MDNA) announced the presentation of updated clinical data from the ongoing Phase 2b trial of MDNA55, an IL-4 targeted toxin,

SAN DIEGO , Nov. 12, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ...

SAN DIEGO , Aug. 26, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced Marty Duvall , chief executive officer, will present and ...

The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...

Phase 3 Toca 5 trial data and details on planned trial in newly diagnosed glioblastoma to be presented at Society for Neuro-Oncology Annual Meeting SAN DIEGO , Nov. 8, 2019 /PRNewswire/ --  Tocagen Inc. ...

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) at the Society for Neuro-Oncology (SNO) Annual Meeting. The data were presented on behalf of the Toca 5 clinical investigators by Timothy Cloughesy, M.D., professor of neurology and director of the neuro-oncology program at the University of California, Los Angeles and principal investigator for the Toca 5 trial.